Keros Therapeutics (KROS) EBT Margin (2019 - 2025)
Historic EBT Margin for Keros Therapeutics (KROS) over the last 6 years, with Q3 2025 value amounting to 61.03%.
- Keros Therapeutics' EBT Margin rose 135874200.0% to 61.03% in Q3 2025 from the same period last year, while for Sep 2025 it was 28.84%, marking a year-over-year increase of 288740000.0%. This contributed to the annual value of 5269.1% for FY2024, which is 960501100.0% up from last year.
- According to the latest figures from Q3 2025, Keros Therapeutics' EBT Margin is 61.03%, which was up 135874200.0% from 181.19% recorded in Q2 2025.
- In the past 5 years, Keros Therapeutics' EBT Margin registered a high of 1583500.0% during Q1 2021, and its lowest value of 541000.0% during Q3 2023.
- For the 5-year period, Keros Therapeutics' EBT Margin averaged around 61896.19%, with its median value being 1503.16% (2024).
- As far as peak fluctuations go, Keros Therapeutics' EBT Margin tumbled by 2000000000bps in 2022, and later skyrocketed by 2000000000bps in 2024.
- Quarter analysis of 5 years shows Keros Therapeutics' EBT Margin stood at 27.6% in 2021, then tumbled by -387bps to 134.37% in 2022, then tumbled by -24077bps to 32486.01% in 2023, then soared by 95bps to 1503.16% in 2024, then skyrocketed by 96bps to 61.03% in 2025.
- Its EBT Margin stands at 61.03% for Q3 2025, versus 181.19% for Q2 2025 and 75.03% for Q1 2025.